Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation.
The efficacy of second allogeneic stem cell transplantation (SCT2) using cord blood (CB) for patients with relapsed hematological malignancies after initial allogeneic stem cell transplantation (SCT1) is unknown. We analyzed the results of SCT2 using single-unit unrelated CB in 34 adult patients with relapsed hematological malignancies after SCT1 in our institution. The patients had acute myeloid leukemia (n = 23), acute lymphoblastic leukemia (n = 7), chronic myelogenous leukemia (n = 2), and myelodysplastic syndrome (n = 2). The cumulative incidence of neutrophil and platelet engraftment was 81.6% at 30 days and 68.5% at 100 days, respectively. With a median follow-up of 40 months, the probability of overall survival at 3 years was 29.0%. The cumulative incidence of relapse and transplant-related mortality at 3 years were 60.7% and 27.2%, respectively. The use of CB could offer the opportunity to receive SCT2 for patients who experienced disease relapse after SCT1 without HLA-identical related or unrelated donors.
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Takaaki
T
Konuma
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Seiko
S
Kato
b Department of Hematology/Oncology , Teikyo University School of Medicine , Tokyo , Japan.
Jun
J
Ooi
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Yasuhiro
Y
Ebihara
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Shinji
S
Mochizuki
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Hiroto
H
Ishii
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Tomomi
T
Takei
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Maki
M
Oiwa-Monna
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Arinobu
A
Tojo
a Department of Hematology/Oncology , The Institute of Medical Science, The University of Tokyo , Tokyo , Japan.
Satoshi
S
Takahashi
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D019337:Hematologic Neoplasms / Q000473:pathology* / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D019233:Retreatment; D012189:Retrospective Studies; D018183:Transplantation Chimera; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D061349:Unrelated Donors; D055815:Young Adult
Acute lymphoblastic leukemia; acute myeloid leukemia; chronic myelogenous leukemia; cord blood transplantation; myelodysplastic syndrome; second allogeneic stem cell transplantation